NAV

Mivavotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mivavotinib
DrugBank Accession Number
DB16849
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 344.394
Monoisotopic: 344.176087483
Chemical Formula
C17H21FN6O
Synonyms
  • 6-{[(1r,2s)-2-Aminocyclohexyl]amino}-7-Fluoro-4-(1-Methyl-1h-Pyrazol-4-Yl)-1,2-Dihydro-3h-Pyrrolo[3,4-C]pyridin-3-One
  • Mivavotinib
External IDs
  • CB-659
  • TAK-659 free base
  • TAK-659F

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Mivavotinib citrate6ZJ8V3Q0H11952251-25-0Not applicable
Mivavotinib hydrochlorideNot Available1952251-28-3PTCFBXMEFRIEGV-ZVWHLABXSA-N

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8QR88H79VX
CAS number
1312691-33-0
InChI Key
MJHOMTRKVMKCNE-NWDGAFQWSA-N
InChI
InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1
IUPAC Name
6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-3-one
SMILES
CN1C=C(C=N1)C1=C2C(=O)NCC2=C(F)C(N[C@@H]2CCCC[C@@H]2N)=N1

References

General References
Not Available
ChemSpider
57583808
BindingDB
50204290
ChEMBL
CHEMBL3979920
PDBe Ligand
7KG
PDB Entries
5tr6

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentPrimary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL) / With and Without MyD88 and/or CD79B Mutations1
1CompletedTreatmentAdvanced Malignant Solid Tumor / Ovarian Carcinoma / Refractory Malignant Solid Neoplasm / Refractory Ovarian Carcinoma1
1TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.353 mg/mLALOGPS
logP1.33ALOGPS
logP0.87Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)12.7Chemaxon
pKa (Strongest Basic)9.91Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area97.86 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity104.86 m3·mol-1Chemaxon
Polarizability35.86 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at July 25, 2022 16:06 / Updated at December 13, 2022 10:46